The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Peter Hillmen(Leeds Teaching Hospitals NHS Trust), Lucio Luzzatto(Muhimbili University of Health and Allied Sciences), Christopher F. Mojcik(Alexion Pharmaceuticals (United States)), Petra Muus(Radboud University Nijmegen), Jeff Szer(The Royal Melbourne Hospital), Antonio M. Risitano(Federico II University Hospital), Alexander Röth(Essen University Hospital), Hubert Schrezenmeier(German Red Cross), Paul Browne(Trinity College Dublin), Neal S. Young(National Institutes of Health), Chieh‐Lin Fu(Cleveland Clinic Florida), Robert A. Brodsky(Johns Hopkins University), Jaroslaw P. Maciejewski(Cleveland Clinic), Ryotaro Nakamura(City of Hope), Russell P. Rother(Alexion Pharmaceuticals (United States)), Modupe Elebute(St. George Hospital), Jörg Schubert(Saarland University), Gèrard Socié(Hôpital Saint-Louis), Anita Hill(Leeds General Infirmary), Scott A. Rollins(Alexion Pharmaceuticals (United States))
Cited by 1,270
Related Papers
HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide
|Biology of Blood and Marrow Transplantation|2008|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k